Benzinga · Oct 27, 2026
Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.
NASDAQ · AVBP
ArriVent BioPharma, Inc. Common Stock
Healthcare · Biotechnology
$15.95
Down-$1.08 (-6.77%)
Updated Oct 31, 2026, 1:52 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.01B
- P/E ratio
- -6.23
- Dividend yield
- 0.00%
- 52-week range
- $11.36 – $35.83
- Volume
- 658.31K
- Avg. volume
- 349.38K
Price performance · AVBP
AVBP price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
AVBP closed at $15.95 after 20 trading sessions, down 43.58% for the selected period.
- Last close
- $15.95
- Period change
- -43.58%
- Period low
- $15.09
- Period high
- $28.46
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $15.87 | $16.42 | $15.73 | $15.95 | 658.31K |
| Oct 28, 2026 | $15.67 | $15.885 | $15.20 | $15.73 | 990K |
| Oct 27, 2026 | $15.45 | $15.69 | $15.00 | $15.40 | 1.58M |
| Oct 26, 2026 | $18.14 | $18.16 | $14.78 | $15.36 | 5.95M |
| Oct 23, 2026 | $19.00 | $21.23 | $18.18 | $21.00 | 3.28M |
| Oct 22, 2026 | $18.93 | $19.68 | $18.78 | $19.20 | 843.7K |
| Oct 21, 2026 | $19.07 | $19.44 | $18.68 | $19.12 | 1.49M |
| Oct 20, 2026 | $17.94 | $18.98 | $17.57 | $18.85 | 817.84K |
| Oct 19, 2026 | $16.82 | $18.14 | $16.7309 | $17.94 | 1.01M |
| Oct 16, 2026 | $16.86 | $17.23 | $16.485 | $16.66 | 1.33M |
| Oct 15, 2026 | $16.40 | $16.91 | $15.97 | $16.79 | 815.7K |
| Oct 14, 2026 | $16.06 | $16.615 | $15.26 | $16.20 | 1.59M |
| Oct 13, 2026 | $16.28 | $16.72 | $15.95 | $16.09 | 1.97M |
| Oct 12, 2026 | $16.57 | $16.78 | $16.262 | $16.46 | 1.34M |
| Oct 9, 2026 | $16.59 | $17.76 | $16.49 | $16.73 | 1.73M |
| Oct 8, 2026 | $16.62 | $16.91 | $15.78 | $16.71 | 2.16M |
| Oct 7, 2026 | $15.245 | $17.345 | $14.9677 | $16.89 | 4.33M |
| Oct 6, 2026 | $12.09 | $15.79 | $11.36 | $15.09 | 19.75M |
| Oct 5, 2026 | $28.00 | $28.70 | $27.02 | $28.46 | 494.76K |
| Oct 2, 2026 | $29.26 | $29.33 | $27.80 | $28.27 | 507.6K |
Latest AVBP news
The latest Smart Investors Daily articles mentioning AVBP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AVBP research
Overview
Company profile and research snapshot.
Company profile
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $40.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | Guggenheim | Buy | — |
| Oct 20, 2026 | B. Riley Securities | Buy | — |
| Oct 16, 2026 | BTIG | Buy | — |
| Oct 8, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 27, 2026
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
ArriVent BioPharma (NASDAQ:AVBP) presented Phase I data for ARR-217, its CDH17-targeting antibody-drug conjugate, or ADC, in heavily pretreated metastatic colorectal cancer patients during a virtual webinar following an ESMO late-breaking oral presentation. The company said the early-stage study sh
Yahoo · Oct 27, 2026
ArriVent BioPharma (AVBP) Advances ARR 217 Into Phase 1b, Is The Selloff Overdone?
ArriVent BioPharma (AVBP) is back in focus after releasing initial Phase 1 data for its CDH17-targeted antibody drug conjugate ARR-217 at the 2026 ESMO Congress and advancing the asset into Phase 1b. For context, ArriVent BioPharma shares closed at US$15.36 on 25 October, with the 1-day share price return declining 26.86% and the 30-day share price return down 46.01%. The 1-year total shareholder return has fallen a more modest 21.19%, suggesting recent enthusiasm around ARR-217 and...
Benzinga · Oct 25, 2026
ArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients
ARR-217 was generally well-tolerated. ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
